Unicycive announces publication of results on oxylanthanum carbonate

Unicycive Therapeutics announced that the peer-reviewed international journal the American Journal of Nephrology has published positive results on the phosphate binding capacity for oxylanthanum carbonate. The Company also announced the adoption of the non-proprietary name, oxylanthanum carbonate by the United States Adopted Name organization, replacing lanthanum dioxycarbonate which has been used in previous publications and company presentations. OLC is Unicycive’s investigational phosphate binding agent utilizing proprietary nanoparticle technology being developed as a lower pill burden option for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The publication, entitled, “High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders,” showed that OLC had the lowest daily phosphate binder dose volume and the lowest volume required to bind 1 g of phosphate compared to five other commercially available phosphate binders. For patients with chronic kidney disease and end-stage kidney disease, regulation of phosphate levels between 3.0 and 4.5 mg/dl is crucial to preserve the proper function of many biological processes, including energy metabolism, skeletal development, and bone integrity. The development of hyperphosphatemia, a condition where serum phosphorus concentration rises above 4.5 mg/dL, is associated with significant pathophysiology and increased mortality risk. Almost 75% of patients on dialysis in the United States have serum phosphorus concentrations greater than 4.5 mg/dL; therefore, a key focus for CKD management is phosphate control. The objective of the study was to assess the volume of OLC required to bind 1 g phosphate and to compare it with other currently available phosphate binders, to determine which binder allows for the highest normalized potency with the lowest daily medication volume. The results of the study showed that the daily phosphate binder dose volume was lowest with oxylanthanum carbonate and highest with sevelamer carbonate